Cyprumed Oral Delivery Technology Enters Clinical Stage With MSD
INNSBRUCK, Austria — September 29, 2026 Cyprumed GmbH announced that MSD has initiated a Phase 1 clinical trial of...
Merck
Advertisement
Merck Gains FDA Label Update for WINREVAIR in PAH
RAHWAY, N.J. — September 22, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has approved an...
Merck Reports Positive Phase 2b/3 BRUNELLO Results for Remigromig
RAHWAY, N.J. — September 24, 2026 Merck announced topline results from the pivotal Phase 2b/3 BRUNELLO study evaluating remigromig...
Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Merck Launches Your Hive of Whole Health for HIV Care
RAHWAY, N.J. — September 18, 2026 Merck announced the launch of Your Hive of Whole Health, a multi-year educational...
Advertisements
Merck and Moderna Report Phase 3 Melanoma Success
Rahway, New Jersey, and Cambridge, Massachusetts, August 19, 2026 Merck and Moderna announced positive topline results from the Phase...
Phanes Therapeutics Gains FDA Fast Track for Spevatamig
San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...
Merck FDA Accepts ENFLONSIA sBLA for Second RSV Season
RAHWAY, N.J., August 6, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental...
Merck & Co., Inc. Expands Global Access to Once-Monthly Alimatravir
RAHWAY, N.J., July 24, 2026 Merck has announced an ambitious global access strategy for alimatravir (MK-8527), its investigational once-monthly...
Gilead Sciences and Merck & Co. Deliver Positive ISLEND Phase 3 Results
FOSTER CITY, Calif. & RAHWAY, N.J., July 22, 2026 Gilead Sciences and Merck announced detailed results from the Phase...
Advertisement
